Anti-Mouse CD45 (Clone 30-F11) – Purified (PhenoCycler-Fusion (CODEX)® Ready)

Clone 30-F11 has been validated for use on PhenoCycler® using [Mouse/Human] [Tissue] [Tissue Type either FFPE or FF] tissue.

Mouse thymus or spleen

This purified antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4.

This DyLight® 594 conjugate is stable when stored at 2-8°C. Do not freeze.

30-F11 recognizes all murine CD45 isoforms.

CD45 is expressed on the surface of all nucleated hematopoietic cells and their precursors, except mature erythrocytes and platelets.

CD45 is a receptor protein tyrosine phosphatase involved in immune cell activation ¹ . It is a large glycoprotein (180-220 kDa) with a broad range of expression in the animal kingdom, including mammals, chicken, shark, and mosquitoes. The cytoplasmic region of CD45 is highly conserved in mammals but its extracellular region varies between species. Additionally, differential splicing leads to several CD45 isoforms which can vary in glycosylation, which in turn can affect CD45 ligand interaction and function. In T cells, isoform expression is dependent on the stage of T cell maturation, activation, and differentiation.

CD45 functions in the immunological synapse of the T cell-antigen presenting cell contact zone that is formed when T cells encounter cognate antigens presented by major histocompatibility (MHC) molecules ¹. CD45 interacts with Src kinases, in particular Lck, to mediate antigen receptor signaling in T and B cells, and is required for the development and activation of lymphocytes. CD45 also interacts with CD3ζ and CD3ε chains as well as tyrosine kinase Zap 70, DAP12, the Janus kinase family, PAG, CD22, among others. With these interactions, CD45 functions to protect the host against viral, bacterial, and fungal infections.

Certain variants of CD45 are associated with autoimmune disease and dysregulation is observed in some cancers ¹. CD45 has been explored as a target of therapeutic modulation for organ transplantation^{1, 2}, autoimmune disease ¹, bone marrow transfusion^{3, 4, 5, 6}as well as cancer radioimmunotherapy^{7, 8}, including a bispecific antibody targeting CD45 and ⁹⁰ Y-DOTA for therapy of myeloid leukemia ⁹.

CD45 is also known as leukocyte common antigen (LCA), lymphocyte antigen 5 (Ly-5) and T200¹⁰.

Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1

P06800

1 Rheinländer A, Schraven B, Bommhardt U. Immunol Lett. 196:22-32. 2018.
2 Orozco JJ, Kenoyer A, Balkin ER, et al. Blood. 127(3):352-359. 2016.
3 Ruffner KL, Martin PJ, Hussell S, et al. Cancer Res. 61(13):5126-5131. 2001.
4 Matthews DC, Badger CC, Fisher DR, et al. Cancer Res. 52(5):1228-1234. 1992.
5 Matthews DC, Martin PJ, Nourigat C, et al. Blood. 93(2):737-745. 1999.
6 Koronyo-Hamaoui M, Sheyn J, Hayden EY, et al. Brain. 143(1):336-358. 2020.
7 Orozco JJ, Balkin ER, Gooley TA, et al. PLoS One. 9(12):e113601. 2014.
8 Dawicki W, Allen KJH, Garg R, et al. Oncotarget. 11(39):3571-3581. 2020.
9 Orozco JJ, Kenoyer AL, Lin Y, et al. Mol Cancer Ther. 19(12):2575-2584. 2020.
10 https://www.uniprot.org/uniprotkb/P06800/entry
11 Coles MC, Veiga-Fernandes H, Foster KE, et al. Proc Natl Acad Sci U S A. 103(36):13457- 13462. 2006.
12 Wilbur DS, Thakar MS, Hamlin DK, et al. Bioconjug Chem. 20(10):1983-1991. 2009.